Amplify Weight Loss Drug & Treatment ETF (THNR) Short Interest Ratio & Short Volume

Short interest is the volume of Amplify Weight Loss Drug & Treatment ETF shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 1,024 shares of THNR short. 0.60% of Amplify Weight Loss Drug & Treatment ETF's shares are currently sold short. Learn More on Amplify Weight Loss Drug & Treatment ETF's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. THNR shares currently have a short interest ratio of 0.8. Learn More on Amplify Weight Loss Drug & Treatment ETF's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.60% of Amplify Weight Loss Drug & Treatment ETF's floating shares are currently sold short.

Amplify Weight Loss Drug & Treatment ETF saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,024 shares, an increase of 93.9% from the previous total of 528 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.60% of Amplify Weight Loss Drug & Treatment ETF's shares are currently sold short. Here is how the short interest of companies compare to Amplify Weight Loss Drug & Treatment ETF: Putnam PanAgora ESG International Equity ETF (0.96%), TrueShares Eagle Global Renewable Energy Income ETF (0.02%), ProShares Ultra Nasdaq Cybersecurity ETF (6.20%), Direxion Daily AI and Big Data Bear 2X Shares (1.29%), First Trust S-Network Streaming and Gaming ETF (0.07%), Putnam Sustainable Leaders ETF (4.86%), Pacer BlueStar Engineering the Future ETF (2.59%), and YieldMax Dorsey Wright Hybrid 5 Income ETF (4.74%).

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($87.50 billion), Invesco QQQ ($42.26 billion), iShares Russell 2000 ETF ($24.79 billion), Salesforce Inc. ($13.16 billion), SPDR S&P Biotech ETF ($10.01 billion), Western Digital Corporation ($9.77 billion), Sandisk Corporation ($8.69 billion), iShares 20+ Year Treasury Bond ETF ($8.06 billion), CoreWeave Inc. ($7.67 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($7.64 billion). View all of the most shorted stocks.

Short selling THNR is an investing strategy that aims to generate trading profit from Amplify Weight Loss Drug & Treatment ETF as its price is falling. THNR shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Amplify Weight Loss Drug & Treatment ETF occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of THNR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including THNR, twice per month. The most recent reporting period available is April, 15 2026.